Study of a National Cohort of Adult Patients With Phenylketonuria

NCT ID: NCT01619722

Last Updated: 2021-04-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

220 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-03-15

Study Completion Date

2020-07-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phenylketonuria (PKU) is a metabolic disease of genetic origin. This is a rare disease (incidence 1 / 16000 births) which is the subject of a systematic neonatal screening in France, because it is treatable by a diet low in phenylalanine. This plan is required upon confirmation of diagnosis and continued until the age of 8 years. The current trend is to continue the scheme at least until adolescence. Unlike other countries, in France there are no recommendations for a plan "for life". Knowledge about the natural history of PKU in adulthood, the effects of pediatric age, the frequency of complicated shapes, and prognostic factors are poorly documented. On the other hand, there is no consensus on the therapeutic management of this disease in adulthood and monitoring that could be directed towards the detection of neurological disorders and nutrition. Social integration and quality of life of adults PKU patients living in France have not been studied.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim off this study is to follow a French cohort of young adult patients with PKU to:

* Describe the evolution of the disease in adulthood and neurological complications associated neuropsychological detect, investigate the prognostic factors for complications
* Describe the metabolic balance of patients
* Collect data on nutritional status,
* Detect osteoporosis
* Studying social integration and quality of life of adult patients with PKU
* Collect biological samples for further study (markers of bone turnover)

Design:

Cohort :

Duration of the inclusion period: 2 years Duration of subject participation: 5 years Total duration of the study: 7 years

JUDGING CRITERIA:

* Complications associated with PKU in adult
* Evolution of neuropsychometric scores
* Bone mineral density by densitometry
* Measuring the quality of life of patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PKU Hyperphenylalaninemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient age ≥ 18 years
* Phenylketonuria (PKU) or moderate persistent Hyperphenylalaninemia (HMP) diagnosed by neonatal screening
* Reading and signing an informed consent
* Membership of a social security system

Exclusion Criteria

* History of severe neurological definite diagnosis could interfere with the detection of neurological disorders associated with PKU
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role collaborator

University Hospital, Tours

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

François MAILLOT, Pr

Role: STUDY_DIRECTOR

CHRU TOURS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHRU-Hôpital Bretonneau - Service de Médecine Interne-Nutrition

Tours, Centre-Val de Loire, France

Site Status

CHU-ANGERS -Médecine Interne

Angers, , France

Site Status

CHU_Service de Médecine Interne Nutrition A2-Hôpital du Haut Levèque

Bordeaux, , France

Site Status

CHU du Morvan-Département de Pédiatrie et génétique médicale,

Brest, , France

Site Status

Hôpital Femme-Mère-Enfant-Centre de Référence des Maladies Héréditaires du Métabolisme de Lyon

Bron, , France

Site Status

CHU de Dijon--Hôpital des Enfants-Centre de Génétique

Dijon, , France

Site Status

CHU de Grenoble-Hôpital MICHALLON-Unité de Neurologie Générale

Grenoble, , France

Site Status

CHU de LILLE-Hôpital Claude HURIEZ-Service d'Endocrinologie

Lille, , France

Site Status

APHM-Hôpital de la Conception -Médecine Interne

Marseille, , France

Site Status

CHU-Service de Réanimation Pédiatrique / Néonatalogie, Consultation spécialisée en Maladies Héréditaires du Métabolisme

Nantes, , France

Site Status

Hôpital Necker Enfants Malades, APHP-Maladies Métaboliques -Service de Pédiatrie

Paris, , France

Site Status

CHU-RENNES-Hôpital Sud-Service de Génétique-Clinique

Rennes, , France

Site Status

CHU de Rouen-Service de Pédiatrie

Rouen, , France

Site Status

CHU de St Etienne-Hôpital Nord-Service de Pédiatrie

Saint-Etienne, , France

Site Status

CHU-Toulouse-Hôpital PURPAN-Service de Médecine Interne

Toulouse, , France

Site Status

University Hospital of NANCY

Vandœuvre-lès-Nancy, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PHRN10/FM-ECOPHEN

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluation of PKU Explore
NCT03168399 COMPLETED NA
GMP Drink for PKU Study
NCT02915510 COMPLETED NA